close
close

Olema Oncology announces new clinical data on palazestrant in combination with ribociclib to be presented at the 2024 ESMO Annual Breast Cancer Congress

Olema OncologyOlema Oncology

Olema Oncology

Olema will host an investor conference call at 8 a.m. ET on May 15, 2024.

SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies targeted. for women’s cancers, today announced that it will present new clinical data from the company’s ongoing Phase 1b/2 clinical study of palazestrant in combination with ribociclib, a CDK4/6 inhibitor, as part of a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Breast Cancer Congress. The 2024 Annual Meeting will take place May 15-17, 2023 in Berlin, Germany.

ESMO Breast Cancer Annual Congress 2024 Poster Presentation Details Available:

Title:

A Phase 1b/2 Study of Palazestrant (OP-1250) in Combination With Ribociclib in Patients With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced and/or Metastatic Breast Cancer (ER+, HER2-), advanced and/or metastatic (ID 407). )

Presentation #:

212P

Date:

Thursday May 16, 2024

Time:

12:00 p.m. CEST (6:00 a.m. ET)

A copy of the poster will be available on the Olema website in the Science section when it is presented at the conference. Poster abstracts will be available on the ESMO Breast Cancer Annual Congress website here.

Webcast and conference call for company investors

Olema will host a webcast and conference call for analysts and investors to review data presented at the ESMO Breast Cancer Annual Meeting 2024 on Wednesday, May 15, 2024, at 8:00 a.m. ET (2:00 p.m. CEST). Please register for the webcast by visiting the Investors & Media section of Olema’s website at olema.com.

About Palazestrant (OP-1250)

Palazestrant (OP-1250) is a novel orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being studied in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-induced transcriptional activity in wild-type and mutant forms of ER+ metastatic breast cancer and has demonstrated antitumor efficacy as well as attractive pharmacokinetics and exposure, favorable tolerability, penetration in the CNS and combinability with CDK4/6 inhibitors. Palazestrant has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of ER+/HER2- metastatic breast cancer that has progressed after one or more lines of endocrine therapy, at least one line of which is administered in combination with a CDK4/6. inhibitor. It is being evaluated both as a monotherapy in an ongoing phase 3 clinical trial, OPERA-01, and in phase 1/2 studies in combination with CDK4/6 inhibitors (palbociclib and ribociclib), a PI3Ka inhibitor (alpelisib) and an mTOR. inhibitor (everolimus). For more information, please visit www.opera01study.com.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming standards of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-based cancers, nuclear receptors and acquired resistance mechanisms. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary and orally available complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), Olema is developing a potent inhibitor of KAT6 (OP-3136). Olema is headquartered in San Francisco and operates in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

IR and media contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
[email protected]